CSL pays $355M for Alentis' kidney and liver drug deal

CSL, an Australian drugmaker, is paying $355 million upfront for a drug still being tested. The drug, called lixudebart, comes from a Swiss biotech named Alentis Therapeutics. It targets rare kidney and liver diseases that slowly scar and destroy organ tissue. If it succeeds in trials, Alentis could earn up to $1.2 billion more. That would push the deal's total value near $1.6 billion.

These diseases don't have many good treatments right now. Lixudebart works by blocking a specific protein involved in the scarring process, instead of just managing symptoms. CSL will fund the Phase 2 and Phase 3 trials. The two companies will split profits roughly 55-45 if it reaches the market. That's a strong vote of confidence in Alentis's early results, but the drug hasn't proven itself in large trials yet.

Keep reading — what to watch

Will lixudebart's early promise hold up in bigger trials? Kidney and liver scarring diseases are notoriously hard to treat. Plenty of promising antibodies have failed at this stage before. The real test comes when CSL's funded Phase 3 trials read out, likely years from now, not at signing.